Litcius/Paper detail

Single-inhaler triple<i>versus</i>dual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety

Samy Suissa

2023European Respiratory Journal16 citationsDOI

Abstract

<h3>Tweetable abstract</h3> <b>A real-world study supports the new 2023 GOLD recommendation that single-inhaler triple therapy be reserved for group E and other exacerbating COPD patients with blood eosinophils count &gt;300, otherwise it is not more effective and is riskier than LAMA-LABA</b> https://bit.ly/3NpWtZC

Topics & Concepts

MedicineInhalerBronchodilatorCOPDDual (grammatical number)Physical therapyIntensive care medicineInternal medicineAsthmaLiteratureArtInhalation and Respiratory Drug DeliveryChronic Obstructive Pulmonary Disease (COPD) ResearchRespiratory Support and Mechanisms
Single-inhaler triple<i>versus</i>dual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety | Litcius